Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study
Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...
FierceBiotech9h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
BioPharma Dive6h
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...
healthday6h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.
Intellia Therapeutics’ NTLA-2002 Shows Promise with Potential Stock Surge
JonesTrading analyst Debanjana Chatterjee has assigned their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
Intellia Therapeutics: Promising Phase 2 Results and Attractive Valuation Spur Buy Recommendation
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
precisionmedicineonline16d
Intellia Starts Phase III Hereditary Angioedema Trial for CRISPR Gene-Editing Therapy
In the HAELO trial, the firm will randomize 60 HAE patients to NTLA-2002 or placebo and compare the number of inflammatory attacks.
Investing8d
Intellia shares maintain positive stance on PhII trial outcomes
The endorsement follows the success of the company's NTLA-2002 product in meeting all primary and secondary endpoints during its Phase II trials. The analyst highlighted the importance of the ...
Investing8d
Intellia shares maintain positive stance on PhII trial outcomes
The endorsement follows the success of the company's NTLA-2002 product in meeting all primary and secondary endpoints during its Phase II trials. The analyst highlighted the importance of the ...